Abatacept

Status
Phase 2
Condition
Myositis ILD
Intervention Type
Subcutaneous (SC) Injection
Funder Type
Organization | University

Drug Details

Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4.

Study Purpose

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
 
Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >